ARID1A ablation leads to multiple drug resistance in ovarian cancer via transcriptional activation of MRP2

Multiple Drug Resistance (MDR) of ovarian cancer is a severe trouble for clinical treatment and always contributes to a bad prognosis. AT-rich interaction domain 1  A (ARID1A) has been recognized as a bona fide tumor suppressor gene in recent years, with the highest mutation rate in ovarian cancer. Previous study illustrated that ARID1A expression is negatively correlated with chemoresistance of ovarian cancer cases. However, the specific role of ARID1A in c hemoresistance of ovarian cancer remains elusive.

Source: Cancer Letters - April 13, 2018 Category: Cancer & Oncology Authors: Qingyu Luo, Xiaowei Wu, Yiping Zhang, Tong Shu, Fang Ding, Hongyan Chen, Pengfei Zhao, Wan Chang, Xiaolin Zhu, Zhihua Liu Tags: Original Articles Source Type: research